Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation

ConclusionThis experimental study shows the prevention application of the combination of ruxolitib and sirolimus post to allogeneic hematopoietic stem cell transplantation is an innovative combination of immunosuppressive therapy, which is safe and tolerable. A randomized clinical trial is underway to evaluate the efficiency of this new approach for aGVHD.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Wang, S., Huang, X., Liu, L., Liang, Y. Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Source Type: research